Niki BioSolutions, Inc. — Form SCHEDULE 13D
Filed July 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Kira Sheinerman filed a Schedule 13D on July 24, 2026, disclosing acquisition of beneficial ownership in Niki BioSolutions, Inc. (CIK 0001734005). The filing identifies Sheinerman's address as 1270 Fifth Avenue, Suite 11H, New York, NY 10029, with Niki BioSolutions' principal address at 116 Village Boulevard, Suite 200, Princeton, NJ 08540. However, the specific share count, percentage of ownership, dollar amount of investment, and acquisition date are NOT disclosed in this document header.
Why this rating
Schedule 13D filing triggers regulatory disclosure but lacks critical quantitative details (shares, %, price, date). Relative to $18.7M asset base, significance depends entirely on undisclosed ownership %; without those facts, cannot assess materiality. Routine disclosure filing without visible business impact.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.